Aidoc vs Butterfly Network

Butterfly Network has a disclosed valuation of $1.5B, while Aidoc's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

Butterfly Network has raised more in total funding at $700M, compared to Aidoc's $370M — a gap of $330M. Combined, the two companies have completed 8 known funding rounds.

Butterfly Network holds the higher Awaira Score at 85/100, compared to Aidoc's 67/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 18-point gap that reflects meaningful differences in scale or traction.

Aidoc was founded by Elad Walach in 2016. Butterfly Network was founded by John Martin in 2011. Visit each company's profile on Awaira for a full founder biography.

Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes. Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine.

Butterfly Network was founded first in 2011, giving it 5 years of additional market experience. Aidoc was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Aidoc has approximately 300 employees, while Butterfly Network has approximately 500-1000. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidoc and Butterfly Network are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.